Search
ProKidney Corp
PROKAdd to Watchlist
2.030USD
+0.140+7.41%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
287.87MMarket Cap
LossP/E TTM
More Details of ProKidney Corp Company
Prokidney Corp. is a late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The Company’s cell therapy platform has the potential to treat CKD using a patient’s own cells. The Company’s lead product candidate, rilparencel (also known as REACT), is a first-in-class, patented, proprietary autologous cell therapy being evaluated in the ongoing Phase III REGEN-006 (PROACT 1) trial to demonstrate the therapy’s potential to preserve kidney function in patients with type 2 diabetes and advanced CKD. Its PROACT 1 is an ongoing Phase III randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with type 2 diabetes and advanced CKD. Its REGEN-007 is a multi-center Phase II open-label, randomized two-arm trial of rilparencel in patients with diabetes, CKD.
ProKidney Corp Info
Ticker SymbolPROK
Company nameProkidney Corp
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Number of employees204
Security typeOrdinary Share
Fiscal year-endJun 30
Address2000 Frontis Plaza Blvd
CityWINSTON-SALEM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27103
Phone13369997028
Websitehttps://prokidney.com/
Ticker SymbolPROK
IPO dateJun 30, 2021
CEOCulleton (Bruce)
Company Executives of ProKidney Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
Dr. Alan M. Lotvin, M.D.
Dr. Alan M. Lotvin, M.D.
Independent Director
Independent Director
--
--
Dr. Brian J. G. Pereira, M.D.
Dr. Brian J. G. Pereira, M.D.
Independent Director
Independent Director
--
--
Mr. Jose Ignacio Jimenez Santos
Mr. Jose Ignacio Jimenez Santos
Independent Director
Independent Director
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Uma Sinha, Ph.D.
Dr. Uma Sinha, Ph.D.
Independent Director
Independent Director
--
--
Mr. James Coulston, CPA
Mr. James Coulston, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Darin J. Weber, Ph.D.
Dr. Darin J. Weber, Ph.D.
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
Chief Regulatory Officer, Senior Vice President- Global Regulatory, Quality Management & Commercial
--
--
Mr. Todd C. Girolamo, J.D.
Mr. Todd C. Girolamo, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Mr. Pablo Legorreta
Mr. Pablo Legorreta
Chairman of the Board
Chairman of the Board
--
--
Mr. William F. (Bill) Doyle
Mr. William F. (Bill) Doyle
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of ProKidney Corp?
The top five shareholders of ProKidney Corp are: Dr. Uma Sinha, Ph.D.
How many institutions hold shares of ProKidney Corp (PROK)?
As of 2026Q1, 181 institutions hold shares of ProKidney Corp, with a combined market value of approximately 50.49M, accounting for 35.56% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 4723430.00.